Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

UCB has sold successfully its stake in Cytec Industries

Brussels (Belgium), March 8, 2007 at 4:30 PM (CET) - UCB announced today that it has sold all its 5,772,857 million shares held in Cytec Industries Inc. ("Cytec") for 248 million euros, realizing a capital gain of more than 20 million euros.

On March 1, 2005, UCB sold its Surface Specialties business to Cytec. Consideration for the transaction was 1,190 million euro in cash and 5,772,857 shares of Cytec. The contractual lock-up period for these Cytec shares expired on February 28, 2007.

About UCB

Headquartered in Brussels (Belgium), UCB (www.ucb-group.com) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.  Employing more than 8,400 people in over 40 countries, UCB achieved revenue of 2.5 billion euro in 2006. UCB is listed on the Euronext Brussels Exchange and owns 87.6% of Schwarz Pharma.

For further enquiries, please contact

Jean-Christophe Donck                                                           

Vice President,                                                                      

Corporate Communications and Investor Relations                    

Tel. +32 2 559 9346      

Asset Download

070308 CYTEK EN


Stay up-to-date on the latest news and information from UCB